- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03983993
Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect)
A Phase II Study of Niraparib in Combination With EGFR Inhibitor Panitumumab in Patients With Advanced Colorectal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. Evaluate the activity of the combination of niraparib with epidermal growth factor receptor (EGFR) inhibitor panitumumab in previously treated patients with rat sarcoma gene (RAS) wild type (WT) metastatic colorectal cancer.
SECONDARY OBJECTIVES:
I. Define the toxicity profile of the combination of niraparib and panitumumab.
II. Evaluate the activity of the combination of niraparib and panitumumab in previously treated patients with metastatic colorectal cancer.
OUTLINE:
Patients receive niraparib orally (PO) once daily (QD) on days 1-28 and panitumumab intravenously (IV) over 60-90 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, every 6 months for 2 years, and then annually for up to 5 years.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Olatunji Alese, MD
- Phone Number: 404-778-2670
- Email: oalese@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, United States, 30342
- Emory Saint Joseph's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participant must have advanced, metastatic RAS wildtype colorectal cancer and must have received at least one line of systemic therapy. Both microsatellite (MSI) high and stable (MSS) patients are eligible
- Participants may have been intolerant of, progressed on, or failed at least one line of systemic chemotherapy. Patients who are currently on first line Oxaliplatin-containing chemotherapy regimen are allowed on the trial if they have remained stable or better ([partial response]PR or [complete response]CR) for at least 4 months on that line of treatment and are being considered for maintenance therapy as standard of care
- Histologic or cytologic diagnosis of colorectal cancer
- Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1
- Absolute neutrophil count ≥ 1,500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin ≥ 9 g/dL
- Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 30 mL/min using the Cockcroft-Gault equation
- Total bilirubin ≤ 1.5 x ULN (≤ 2.0 in patients with known Gilberts syndrome) OR direct bilirubin ≤ 1 x ULN
- Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN
- Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment
- Female participant has a negative urine or serum pregnancy test within 7 days prior to taking study treatment if of childbearing potential and agrees to abstain from activities that could result in pregnancy from screening through 180 days after the last dose of study
- Male participant agrees to use an adequate method of contraception starting with the first dose of study treatment through 180 days after the last dose of study treatment
- Participant must be able to provide written informed consent
Exclusion Criteria:
- Participant must not be simultaneously enrolled in any interventional clinical trial
- Prior therapy with poly ADP (adenosine diphosphate) ribose polymerase (PARP) inhibitors or with EGFR inhibitors approved for the treatment of colorectal cancer (cetuximab or panitumumab)
- Patients with a history of interstitial pneumonitis or pulmonary fibrosis, or evidence of interstitial pneumonitis or pulmonary fibrosis during screening
- Inability to take oral medications
- Participant has had radiation therapy encompassing > 20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to day 1 of protocol therapy
- Participant must not have a known hypersensitivity to components or excipients of niraparib or panitumumab
- Participant must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent
- Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
- Participant must not have had diagnosis, detection, or treatment of another type of cancer ≤ 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated)
- Participant must not have known active, symptomatic brain or leptomeningeal metastases.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (niraparib, panitumumab)
Patients receive 200 or 300 mg niraparib orally once daily on days 1-28 and 6 mg/kg panitumumab intravenously over 60-90 minutes on days 1 and 15.
Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical benefit rate (CBR)
Time Frame: Up to 5 years post treatment
|
The efficacy, as measured by clinical benefit rate (CBR), will be assessed for the total number of patients enrolled.
CBR = (Complete Response + Partial Response + Stable Disease [CR +PR + SD] rate.
Response will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria using an independent review.
|
Up to 5 years post treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to 5 years post treatment
|
Objective response rate (ORR) is defined as the percentage of patients with complete response (CR) or partial response (PR), as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria using an independent review.
|
Up to 5 years post treatment
|
Duration of response (DOR)
Time Frame: Up to 5 years post treatment
|
Duration of response (DOR) is defined as the time from the initial response (complete response [CR] or partial response [PR]) until the time of first documentation of disease progression, as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria using an independent review.
|
Up to 5 years post treatment
|
Progression free survival (PFS)
Time Frame: Up to 5 years post treatment
|
For progression free survival (PFS), progression or death from any cause will be defined as the event.
Progression will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria using an independent review.
Patients will be censored at time of last follow-up.
|
Up to 5 years post treatment
|
Overall survival (OS)
Time Frame: Up to 5 years post treatment
|
For overall survival (OS), death from any cause will be defined as the event.
Patients will be censored at time of last follow-up.
|
Up to 5 years post treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Carcinoma
- Colorectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Poly(ADP-ribose) Polymerase Inhibitors
- Niraparib
- Panitumumab
Other Study ID Numbers
- IRB00107377
- P30CA138292 (U.S. NIH Grant/Contract)
- NCI-2018-02757 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- Winship4517-18 (Other Identifier: Emory University Hospital/Winship Cancer Institute)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Microsatellite Stable
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers Squibb; BayerActive, not recruitingColon Cancer | Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon CancerUnited States
-
Sun Yat-sen UniversityActive, not recruitingAdvanced Microsatellite Stable Colorectal Cancer | Metastatic Microsatellite-stable Colorectal CancerChina
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Merck Sharp & Dohme LLCActive, not recruitingHigh Tumor Mutation Burden | High TMB (Tumor Mutation Burden) | MSS (Microsatellite Stable)United States
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
Fudan UniversityNot yet recruitingColorectal Cancer | Microsatellite Stable Colorectal CarcinomaChina
-
MedImmune LLCWithdrawnMicrosatellite-stable Colorectal Cancer
-
Bristol-Myers SquibbActive, not recruitingMicrosatellite Stable Colorectal Cancer | Mismatch Repair Proficient Colorectal Cancer | Microsatellite Unstable Colorectal Cancer | Mismatch Repair Deficient Colorectal CancerUnited States, Australia, Belgium, Canada, Ireland, Italy, Spain, France
-
MedImmune LLCTerminatedMetastatic Microsatellite-stable Colorectal CancerUnited States, Spain, France, Australia, Canada
-
Massachusetts General HospitalBristol-Myers SquibbActive, not recruitingMetastatic Microsatellite Stable Colorectal CancerUnited States
Clinical Trials on Panitumumab
-
University of Alabama at BirminghamRecruiting
-
Spanish Cooperative Group for the Treatment of...AmgenCompleted
-
Radboud University Medical CenterTerminatedIrresectable Squamous Cell or Adenocarcinoma of the OesophagusNetherlands
-
TakedaCompleted
-
WiSP Wissenschaftlicher Service Pharma GmbHGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHTerminatedUrinary Bladder CancerGermany
-
Cliniques universitaires Saint-Luc- Université...Terminated
-
Gruppo Oncologico del Nord-OvestCompletedMetastatic Colo-rectal CancerItaly
-
University of UtahTerminatedKRAS and NRAS Wild-type Colorectal CancerUnited States
-
Hellenic Cooperative Oncology GroupCompleted
-
Matteo's FriendsRecruitingRecurrence Free SurvivalItaly